The three-arm, randomized, phase III TRIANGLE trial has set a new first-line standard in younger patients with mantle cell lymphoma (MCL), showing that the addition of ibrutinib to standard immunochemotherapy improves efficacy [1]. Previously untreated patients aged 18-65 years who were eligible for autologous stem cell transplantation (ASCT) were randomized to either induction treatment with R-CHOP and R-DHAP followed by ASCT (group A; n = 288) or one of two experimental arms: In group A+I (n = 292), ibrutinib was added to R-CHOP and was administered as fixed-duration maintenance for two years after ASCT.

Recent advances have transformed the management of Waldenström macroglobulinemia (WM), particularly with the advent of targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors. These innovations have addressed longstanding challenges including resis­tance, intolerance, and the need for personalized approaches (enabling therapy also for those deemed unfit for chemotherapy).

In the context of follicular lymphoma treatment, there is a clear unmet need for patients who have experienced early progression (progression within 24 months of front-line therapy, POD24), as well as those who are refractory to treatment and present with other high-risk features. At ASH 2024, promising efficacy and safety data were reported for the five molecules nemtabrutinib, zanubrutinib, BGB-16673, epcoritamab, and mosunetuzumab [1-6].

In patients with treatment-naïve chronic lymphocytic leukemia (CLL), the multicenter, open-label, randomized, phase III AMPLIFY trial was initiated to evaluate fixed-duration treatment with acalabrutinib plus venetoclax ± obinutuzumab compared to investigator’s choice of chemoimmunotherapy (CIT).